August 29, 2023 – Page 13

Kraken Robotics Reports Strong Q2 2023 Financial Results

Written by Customer Service on August 29, 2023. Posted in Earnings Releases And Operating Results.

Reiterates F2023 Guidance of $66-78 Million in Revenue and $12-17 Million in Adjusted EBITDA ST. JOHN’S, Newfoundland and Labrador, Aug. 29, 2023 (GLOBE NEWSWIRE) — Kraken Robotics Inc. (TSX-V: PNG, OTCQB: KRKNF) (“Kraken” or the “Company”), announced it has filed financial results for the quarter ended June 30, 2023 (“Q2 2023”). Management Comments “With solid results in the first half of 2023, we look forward to a continued ramp in the 2nd half of 2023 and beyond,” said Kraken President and CEO Greg Reid. “Our sonar and subsea power business are seeing strong growth opportunities, and with significant contracts in hand, we have been focused on adding depth across the organization and sharpening our execution as we scale. With the recent expiry of share purchase warrants, the repayment of the acquisition...

Oculis Reports Q2 and First Half 2023 Financial Results and Provides Company Update

Written by Customer Service on August 29, 2023. Posted in Earnings Releases And Operating Results.

Achieved two landmark milestones with OCS-01, Oculis’ lead product candidate as first investigational eye drop for both front and back of the eye indications: positive topline results in Phase 3 DIAMOND Stage 1 trial for diabetic macular edema (DME) announced in May, and in Phase 3 OPTIMIZE trial for inflammation and pain following cataract surgery announced in August Advancing clinical programs with OCS-01, OCS-02 and OCS-05, including first patient enrolled in the investigator-initiated LEOPARD trial evaluating OCS-01 for treatment of cystoid macular edema (CME) Successfully listed on NASDAQ and raised gross proceeds of approximately $146 million during the first half of 2023 ZUG, Switzerland, and BOSTON, Aug. 29, 2023 (GLOBE NEWSWIRE) — Oculis Holding AG (Nasdaq: OCS) (“Oculis” or the “Company”), a global biopharmaceutical...

StateHouse Launches Intercanopy Lighting Validation Study

Written by Customer Service on August 29, 2023. Posted in Public Companies.

Commercial cannabis cultivator partners with other growers, Grow Light Design and The Cannabis Research Coalition to examine the impact of Flower Direct Cannabis Cultivation strategies on cannabis flower yield, biomass category ratio and secondary metabolite production. SAN DIEGO and TORONTO, Aug. 29, 2023 (GLOBE NEWSWIRE) — StateHouse Holdings Inc. (“StateHouse” or the “Company”) (CSE: STHZ) (OTCQX: STHZF), a California-focused, vertically integrated cannabis enterprise, today announced the launch of the Intercanopy Lighting Validation Group (“ICLVG”) study. Initiated by Statehouse and conducted in partnership with the Cannabis Research Coalition (“CRC”), and a group of anonymous global growers (“Growers”), the study will determine the impact of Flower Direct Cannabis Cultivation (“FDC2”) lighting...

Amicus Therapeutics Announces Presentation and Posters at the SSIEM Annual Symposium 2023

Written by Customer Service on August 29, 2023. Posted in Public Companies.

PHILADELPHIA, Aug. 29, 2023 (GLOBE NEWSWIRE) — Amicus Therapeutics (Nasdaq: FOLD), today announced that one oral presentation and five posters across its development programs will be included at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2023, being held August 29 – September 1, 2023 in Jerusalem, Israel. Oral Presentation: Pompe Disease: Abstract Title: Switching treatment from alglucosidase alfa to cipaglucosidase alfa plus miglustat positively affects motor function and quality of life in patients with late-onset Pompe disease Presenter: Priya Kishnani, MD, MBBS, Duke University Medical Center, Durham, NC, U.S.A. Session: Clinical Studies & Outcomes I Date and time: Wednesday, August 30, 8:45-9:00 a.m. I.D.T. Location: Oren 2 Poster Sessions: Fabry Disease: Abstract Title: Multiorgan...

ApartmentLove Completes Integration with Major North American Vacation Rental Supplier BookingPal

Written by Customer Service on August 29, 2023. Posted in Public Companies.

TORONTO, Aug. 29, 2023 (GLOBE NEWSWIRE) — ApartmentLove Inc. (CSE: APLV) (OTCQB: APMLF) (“ApartmentLove” or the “Company”), a leading provider of online home, apartment, and vacation rental marketing services to property managers, owners, renters, and vacationers from around the world is pleased to announce the successful completion of all engineering to integrate the Company’s Short-Term Vacation Rental (“STVR”) website OwnerDirect.com with BookingPal, a major North American STVR listing supplier. Providing access to thousands of STVR listings across the United States, Mexico, the Caribbean, and elsewhere abroad, the integration with BookingPal is expected to significantly increase the number of high-quality STVR properties on OwnerDirect.com providing more and better choice for the millions of users searching vacation rentals...

Brunswick in Partnership With Midland Begins a First Exploration Program for Lithium on the Mythril Project North of Patriot Battery Metals Corvette Project

Written by Customer Service on August 29, 2023. Posted in Public Companies.

Figure 1 James Bay Main Lithium Project Figure 2 Mythril Lithium Project Area MONTREAL, Aug. 29, 2023 (GLOBE NEWSWIRE) — Midland Exploration Inc. (“Midland” or the “Corporation”) (TSX-V: MD) is pleased to announce the start of a first exploration program for lithium mineralization on its Mythril project, operated by Brunswick Exploration Inc. (“Brunswick”). The Mythril project is under an option agreement with Brunswick since November 2022 (see Midland press release of November 10, 2022). The Mythril project is located in the Eeyou Istchee James Bay region immediately north of Patriot Battery Metals Inc.’s (“Patriot”) Corvette project. Highlights New structural interpretation, derived from magnetic data, reveals north-east trending structures, oriented like Patriot’s CV13 pegmatites; Lithium lake bottom anomalies...

Rivalry Reports 192% Growth in Handle and 60% Growth in Revenue for Q2 2023, Projects Profitability in H1 2024

Written by Customer Service on August 29, 2023. Posted in Public Companies.

Bespoke Product, Creative Marketing Deliver Significant Year-Over-Year Growth, Cost Efficiencies, and Strong Revenue Trajectory; Company Forecasts Profitability in H1 2024 Betting handle of $112.2 million,¹ up 192% year-over-year, while reducing marketing spend 6% year-over-year. Revenue of $8.5 million grew 60% year-over-year. Gross profit of $3.8 million was up 86% year-over-year. Increased product depth and organic marketing build on user acquisition and engagement ahead of tentpole esports events in H2, acquiring 44% more new customers YoY at a 41% lower cost of customer acquisition; average betting handle per customer increased by 63% year-over-year. Momentum has continued into the third quarter with $46.6 million in betting handle in July 2023, a single-month record, up 99% year-over-year. Company provides guidance, anticipates...

Apellis Announces Corporate Restructuring to Drive Growth of SYFOVRE® (pegcetacoplan injection) and EMPAVELI® (pegcetacoplan), Positioning Company for Long-Term Success

Written by Customer Service on August 29, 2023. Posted in Public Companies.

Maximizing global leadership of SYFOVRE in geographic atrophy (GA) Streamlining the EMPAVELI business and prioritizing development of systemic pegcetacoplan in IC-MPGN/C3G Focusing research initiatives on retina and CNS Anticipated total cost savings of up to $300 million through 2024, which includes an approximately 25% reduction in current workforce and a reduction in external expenses WALTHAM, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) (the “Company”), a global biopharmaceutical company and leader in complement, today announced a corporate restructuring to drive growth of SYFOVRE® (pegcetacoplan injection) and EMPAVELI® (pegcetacoplan), positioning Apellis for long-term success. This restructuring will include cost reduction initiatives that align with the Company’s near-term...

Eagle Pharmaceuticals Announces Positive Type C Meeting with FDA for EA-114, an Estrogen Receptor Antagonist Used in the Treatment of Metastatic Breast Cancer in Post-Menopausal Women

Written by Customer Service on August 29, 2023. Posted in Public Companies.

Eagle plans to file a new drug application (“NDA”) for EA-114 in 2024 EA-114 is anticipated to meaningfully optimize the dosing regimen for all fulvestrant patients and provide the opportunity for a more personalized treatment regimen in subpopulations, which represent over 50% of patients WOODCLIFF LAKE, N.J., Aug. 29, 2023 (GLOBE NEWSWIRE) — Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced a positive Type C meeting with the U.S. Food and Drug Administration (“FDA”). Eagle and the FDA agreed on a path forward to advance the clinical development of EA-114, an estrogen receptor antagonist used in the treatment of breast cancer in post-menopausal women. EA-114 has the potential to provide healthcare providers with a formulation that meaningfully optimizes the dosing regimen for all fulvestrant...

Castellum Announces the Award of a $3 million Contract to its Specialty Systems, Inc. Subsidiary

Written by Customer Service on August 29, 2023. Posted in Public Companies.

Castellum Announces the Award of a $3 million Contract to its Specialty Systems, Inc. Subsidiary Castellum, Inc. (NYSE-American: CTM) (“Castellum”) announces that its Specialty Systems, Inc. subsidiary has been awarded a $3 million, 14-month U.S. Navy contract – http://castellumus.com/ POTOMAC, Md., Aug. 29, 2023 (GLOBE NEWSWIRE) — Castellum, Inc. (NYSE-American: CTM) (“Castellum”) announces that its Specialty Systems, Inc. subsidiary has been awarded a $3 million, 14-month U.S. Navy contract. With this contract, Castellum furthers the commitment to its U.S. Navy mission. “This is an important contract award as it will permit us to support our U.S. Navy mission customer by maximizing the readiness of the forces as they address a multitude of global threats,” said Mark Fuller, President and Chief Executive Officer...

Day: August 29, 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice